Debt-to-Equity Conversion Plan with PDL BioPharma, Inc., Strengthens Company's Balance Sheet to Support Leadership Position in Refractive Cataract Surgery

INCLINE VILLAGE, Nev. , May 3, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2017 including: Total revenues of $45.4 million for the three months ended March 31, 2017 .

INCLINE VILLAGE, Nev. , April 26, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2017 financial results for the period ended March 31, 2017 , on Wednesday, May 3, 2017 , after market close.

INCLINE VILLAGE, Nev. , April 24, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that on April 21, 2017 , the Company entered into a settlement agreement with certain subsidiaries of Merck & Co., Inc. (" Merck ") to resolve the patent infringement

INCLINE VILLAGE, Nev. , April 6, 2017 /PRNewswire/ --  PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Friday, June 9, 2017 , at 10:00 a.m. Pacific Time for all stockholders of record on April 17, 2017 .

INCLINE VILLAGE, Nev. , March 14, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will present at the Oppenheimer 27 th Annual Healthcare Conference next week in New York .

INCLINE VILLAGE, Nev. , March 2, 2017 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will present at two investor conferences in March. Cowen and Company 37 th Annual Health Care Conference Wednesday,

INCLINE VILLAGE, Nev. , March 1, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the fourth quarter and year ended December 31, 2016 including: Total revenues of $66.5 million and $244.3 million for the three and twelve months ended

INCLINE VILLAGE, Nev. , March 1, 2017 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that the company's board of directors has authorized the repurchase of up to $30 million of the company's common stock through March 2018 .  Purchases may be made in open-market

INCLINE VILLAGE, Nev. , Feb. 22, 2017 /PRNewswire/ --  PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter, year-end 2016 financial results for the period ended December 31, 2016 , on Wednesday, March 1, 2017 , after market close.

INCLINE VILLAGE, Nev. , Feb. 17, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will participate in a fireside chat at the 2017 RBC Capital Markets Global Healthcare Conference next week in New

INCLINE VILLAGE, Nev. , Nov. 22, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) announced today the closing of its previously announced offering of convertible senior unsecured notes due December 1, 2021 (2021 Notes).  PDL issued $150.0 million aggregate principal amount of 2021

INCLINE VILLAGE, Nev. , Nov. 22, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the 28 th Annual Piper Jaffray Healthcare Conference next week in New York .

INCLINE VILLAGE, Nev. , Nov. 17, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) announced today that it has agreed to sell $150.0 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2021 (the Notes) in an underwritten public offering.  The conversion rate

INCLINE VILLAGE, Nev. , Nov. 15, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) announced today that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of new convertible senior notes due December 1, 2021 (the Notes) under PDL's